Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Despite the increased detection of prostate cancer at an early stage, men are still dying of this disease. Management of advanced disease focuses on controlling the disease process, palliation of symptoms and improving quality of life. In this review, the basis for androgen deprivation in hormone-dependent disease is discussed and the role of maximum and intermittent androgen deprivation, as well as management options for hormone-refractory disease is addressed. Local radiotherapy continues to be of importance in pain control and the maintenance of quality of life. Radiopharmaceuticals and bisphosphonates also have a role to play, the latter particularly in the reduction of skeletal-related events. Chemotherapy in hormone-refractory disease is now well established following pivotal trials demonstrating a survival benefit with docetaxel. The emergence of novel agents targeting growth factors, angiogenesis and immunotherapy present exciting possibilities for future treatment.

Original publication

DOI

10.1586/14737140.6.5.813

Type

Journal article

Journal

Expert Rev Anticancer Ther

Publication Date

05/2006

Volume

6

Pages

813 - 821

Keywords

Androgen Antagonists, Androgens, Angiogenesis Inhibitors, Diphosphonates, Drug Resistance, Neoplasm, Humans, Immunotherapy, Male, Neoplasm Metastasis, Prostatic Neoplasms, Radiopharmaceuticals, Survival Analysis